In human pituitary adenoma cultures, novel analogues were 30-40% more potent than lanreotide in suppressing GH (P < 0.05).
In plain wordsIn cells from human pituitary tumors, lanreotide was less potent than novel analogues at suppressing GH.
- Peptide
- Lanreotide
- Outcome
- DecreaseRelative potency for GH suppression
- Study
humann: not reported in source
Primary human GH-secreting pituitary adenoma cultures- Comparator
- Novel SSTR2- or SSTR5-selective analogues
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
- Studied dose
- Dose not stated
Source sentences
However, novel analogues from both groups were 30-40% more potent than octreotide and lanreotide in suppressing GH (P < 0.05).
1 context sentence(design, population, supporting numbers)
We now tested SSTR subtype-selective analogues in primary human GH- and PRL-secreting pituitary adenoma cultures.